The
global market for peptide therapeutics market derives much of its
demand from the treatment of cancer and diabetes. The rising
incidence of these diseases is making way for the advancement of
peptide drugs, which in turn is propelling the global peptide
therapeutics market. Additionally, the technical advancements in
peptide drugs have resulted in a reduction in total production cost,
fueling the production process of new peptide drugs.
Browse
Full Global Peptide Therapeutics Market Report With Complete TOC @
http://www.transparencymarketresearch.com/peptide-therapeutics-market.html
On
the other hand, API manufacturers are facing a tough challenge from
the complex structure of peptides. Other than this, the lack of
regulatory standards to arbitrate developments in peptide drugs is
also hampering the growth of the peptide therapeutics market.
However, biotech enterprises are identifying prospects for future
growth in collaboration with major pharmaceutical firms across the
globe.The global peptide therapeutics market is expected to expand at
a CAGR of 2.8% during the period from 2014 to 2020 in order to reach
US$23.7 billion by 2020. The market had reached a value of US$18.9
billion in 2013.
Market
for Respiratory Disorders Poised to Grow at Highest CAGR between 2014
and 2020
Peptide
therapeutics find application in the treatment of various kinds of
ailments such as cardiovascular, nervous, gastrointestinal,
respiratory, metabolism-related, in addition to cancer, various
infections, and pain. The cancer market was the dominant application
segment of the peptide therapeutics market in 2013. However, the
respiratory disorder market segment is projected to develop at the
highest CAGR during the period from 2014 to 2020 owing to the recent
approval of lucinactant, sold under the brand name Surfaxin.
The
global peptide therapeutics market is analyzed on three fronts: Route
of administration, marketing status, and regional distribution of the
global industry. Based on route of administration, parenteral and
oral are the two segments of this market, while branded peptide
therapeutics and generic peptide therapeutics are the segments of the
global market on the basis of marketing status. The market for
generic peptides is expected to do well in the next few years on
account of patent expirations expected in the branded peptide market
in the near future.
Asia
Pacific to Report Highest Compound Annual Growth Rate from 2014 to
2020
Regionally,
the global peptide therapeutics market is distributed among North
America, Europe, Asia Pacific, and the Rest of the World, wherein the
global market is dominated by the North American and European
markets, which jointly occupy over 60% of the global market. However,
in spite of the dominance of these regions in the global market, the
peptide therapeutics market in Asia Pacific is poised to grow at the
highest CAGR during the period from 2014 to 2020.The peptide
therapeutics market in Asia Pacific is majorly driven by the rapid
growth of this market in China, India, and Japan. The rise in
economic stability and increased awareness pertaining to the
treatment of various diseases are the major factors fueling the
growth of the market in this region.
Browse
Full
Press Release Report:
http://www.transparencymarketresearch.com/pressrelease/peptide-therapeutics-market.htm
Japan
is the second largest market in the global individual pharmaceutical
industry, whereas China and India have a huge population pool
suffering from various diseases and ailments that are cured with the
help of peptide therapeutics. These factors are expected to establish
Asia Pacific as the most promising market for peptide therapeutics in
the near future. China and India are also emerging as some of the
largest peptide API suppliers in the world.
Amgen,
Inc., Bachem Holding AG, AstraZeneca Plc, CordenPharma Int. GmbH,
Ipsen S.A., Eli Lilly and Co., Lonza Group Ltd., Novartis AG, Merck &
Co., Inc., Novo Nordisk A/S, Roche Holdings AG, PolyPeptide Group,
Sanofi, Millennium Pharmaceuticals Inc., Teva Pharmaceutical
Industries Ltd., and Takeda Pharmaceutical Co. Ltd. are the major
enterprises working in the global peptide therapeutics industry. The
market is mostly concentrated as Takeda, Teva, and Novo Nordisk
collectively hold more than 50% of the overall peptide therapeutics
market.
The
forthcoming patent expiry of Copaxone by Teva and Velcade by
Millennium Pharma and the projected launch of their generic
alternatives are expected to change the dynamics of the global
peptide therapeutics market in the near future.
Request
a Brochure of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=418
About
Us
Transparency
Market Research (TMR) is a market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We have an
experienced team of Analysts, Researchers, and Consultants, who use
proprietary data sources and various tools and techniques to gather,
and analyze information. Our business offerings represent the latest
and the most reliable information indispensable for businesses to
sustain a competitive edge.
Each
TMR Syndicated Research report covers a different sector — such as
pharmaceuticals, chemical, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
our syndicated reports thrive to provide clients to serve their
overall research requirement.
Contact
Mr.
Nachiket Ghumare
90
State Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
No comments:
Post a Comment